Bempedoic Acid Dosage
Medically reviewed by Drugs.com. Last updated on Mar 16, 2022.
Applies to the following strengths: 180 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Heterozygous Familial Hypercholesterolemia
180 mg orally once a day
Comments:
-This drug should be given with maximally tolerated statin therapy.
-Lipid levels should be checked within 8 to 12 weeks of treatment initiation.
Uses: As an adjunct to diet and maximally tolerated statin therapy for the treatment of heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease in those requiring additional LDL-C lowering.
Usual Adult Dose for Cardiovascular Risk Reduction
180 mg orally once a day
Comments:
-This drug should be given with maximally tolerated statin therapy.
-Lipid levels should be checked within 8 to 12 weeks of treatment initiation.
Uses: As an adjunct to diet and maximally tolerated statin therapy for the treatment of heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease in those requiring additional LDL-C lowering.
Renal Dose Adjustments
Mild to moderate renal impairment (eGFR 30 mL/min/1.73 m2 or greater): No adjustment recommended
Severe renal impairment (eGFR less than 30 mL/min/1.73 m2): Use caution as there is limited experience
Liver Dose Adjustments
Mild to moderate hepatic impairment (Child Pugh A or B): No adjustment recommended
Severe hepatic impairment: Data not available
Precautions
CONTRAINDICATIONS: None
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
-Take orally once a day with or without food
General:
-This drug, in combination with maximally tolerated statins (with or without other lipid modifying agents) decreases LDL-C, non-high-density lipoprotein cholesterol, apolipoprotein B, and total cholesterol.
-Concomitant use with simvastatin or pravastatin my increase the risk of simvastatin or pravastatin associated myopathy as it may increase the serum concentrations of these drugs.
Monitoring:
-Lipid levels should be checked within 8 to 12 weeks of therapy initiation
-Serum uric acid levels should be obtained as clinically indicated
Patient advice:
-Patients should be instructed to read the US FDA-approved patient labeling (Patient Information).
-Patients should be instructed to report tendinitis or tendon rupture symptoms.
-Patients should be instructed to report signs or symptoms of hyperuricemia.
-Patients should be instructed to speak with their healthcare provider if they are or are planning to become pregnant or breastfeeding.
More about bempedoic acid
- Side effects
- Drug interactions
- During pregnancy
- Reviews (1)
- En español
- Drug class: miscellaneous antihyperlipidemic agents
Patient resources
- Other brands
- Nexletol
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.